Table 1 Filament types from cases 1–25

Case	Disease	Age (years)	T185S SNP	TMEM106B filaments	Other filaments
1	AD	79	SS	I-s (21%)/I-d (5%)	Aβ (37%)/tau (37%)
2	FAD	67	TT	I-s (16%)/I-d (1%)	Aβ (27%)/tau (56%)
3	EOAD	58	TT	I-s (31%)/I-d (<1%)	Aβ (15%)/tau (54%)
4	PA	59	TS	I-s (23%)/I-d (1%)	Aβ (76%)
5	CBD	74	TS	I-s (6%)/I-d (1%)	Tau (93%)
6	CBD	79	TS	I-s (11%)/I-d (1%)	Tau (88%)
7	FTDP-17T	55	TT	I-s (23%)/I-d (3%)	Tau (74%)
8	AGD	85	TS	III-s (8%)	Tau (92%)
9	AGD	90	TT	I-s (29%)/I-d (3%)	Tau (68%)
10	LNT	66	TT	I-s (17%)/I-d (2%)	Tau (81%)
11	ARTAG	85	SS	III-s (67%)	Tau (11%)/Aβ (22%)
12	PD	87	SS	III-s (13%)	Unknown (45%)/tau (42%)
13	PDD	64	TT	I-s (50%)/I-d (6%)	Aβ (28%)/unknown (16%)
14	FPD	67	SS	III-s (4%)	Unknown (96%)
15	DLB	74	SS	III-s (36%)	Unknown (64%)
16	DLB	73	TS	I-s (30%)/I-d (1%)	Aβ (62%)/unknown (7%)
17	MSA	85	SS	III-s (27%)/III-d (<1%)	αS (73%)
18	MSA	70	TS	I-s (13%)/I-d (5%)	αS (82%)
19	MSA	68	TT	IIa-s (11%)/IIb-s (4%)/II-d (<1%)	αS (85%)
20	FTLD-TDP-A	66	TS	I-s (21%)/I-d (30%)	Aβ (46%)/unknown (3%)
21	FTLD-TDP-C	65	SS	III-s (77%)	Unknown (23%)
22	ALS-TDP-B	63	SS	III-s (46%)/III-d (10%)	Unknown (24%)/Aβ (19%)
23	Control	75	TS	I-s (83%)/I-d (17%)	Undefined (<1%)
24	Control	84	TS	I-s (67%)/I-d (33%)	Undefined (<1%)
25	Control	101	TT	I-s (92%)/I-d (8%)	Undefined (<1%)

TMEM106B filaments are indicated according to their protofilament fold (I–III) and whether they comprise one (-s) or two (-d) protofilaments. Percentages of protein filament types were calculated on the basis of the number of extracted segments from manually picked filaments (and in some cases on the number of segments after 2D classification to separate TMEM106B filaments comprising one or two protofilaments). These values may not reflect what is present in the brain, nor be directly comparable between cases. αS, α-synuclein; AD, Alzheimer’s disease; AGD, argyrophilic grain disease; ALS-TDP-B, amyotrophic lateral sclerosis with TDP-43 inclusions type B; ARTAG, ageing-related tau astrogliopathy; CBD, corticobasal degeneration; control, individual with normal neurology; DLB, dementia with Lewy bodies; EOAD, early-onset Alzheimer’s disease; FAD, familial Alzheimer’s disease; FPD, familial PD; FTDP-17T, familial frontotemporal dementia and parkinsonism linked to chromosome 17 caused by MAPT mutations; FTLD-TDP-A, familial frontotemporal lobar degeneration with TDP-43 inclusions type A; FTLD-TDP-C, FTLD with TDP-43 inclusions type C; LNT, limbic-predominant neuronal inclusion body 4R tauopathy; MSA, multiple system atrophy; PA, pathological ageing; PD, Parkinson’s disease; PDD, PD dementia; SNP, single nucleotide polymorphism.

Search